Drakopoulos et al. (2016) suggested that the usage of hCG to trigger final maturation of oocytes instead of GnRH agonist will increase the risk of OHSS, especially in high ovarian response patients [27]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.